Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment

Detalles Bibliográficos
Autores principales: Manouchehri, Navid, Stüve, Olaf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970673/
https://www.ncbi.nlm.nih.gov/pubmed/33796142
http://dx.doi.org/10.1177/1756286421990500
_version_ 1783666458384924672
author Manouchehri, Navid
Stüve, Olaf
author_facet Manouchehri, Navid
Stüve, Olaf
author_sort Manouchehri, Navid
collection PubMed
description
format Online
Article
Text
id pubmed-7970673
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-79706732021-03-31 Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment Manouchehri, Navid Stüve, Olaf Ther Adv Neurol Disord Letter to the Editor SAGE Publications 2021-02-01 /pmc/articles/PMC7970673/ /pubmed/33796142 http://dx.doi.org/10.1177/1756286421990500 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Letter to the Editor
Manouchehri, Navid
Stüve, Olaf
Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
title Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
title_full Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
title_fullStr Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
title_full_unstemmed Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
title_short Should ocrelizumab be used in non-active primary progressive multiple sclerosis? Time for a re-assessment
title_sort should ocrelizumab be used in non-active primary progressive multiple sclerosis? time for a re-assessment
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970673/
https://www.ncbi.nlm.nih.gov/pubmed/33796142
http://dx.doi.org/10.1177/1756286421990500
work_keys_str_mv AT manouchehrinavid shouldocrelizumabbeusedinnonactiveprimaryprogressivemultiplesclerosistimeforareassessment
AT stuveolaf shouldocrelizumabbeusedinnonactiveprimaryprogressivemultiplesclerosistimeforareassessment

Ejemplares similares